Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1

22 May 2020

Abstract excerpt

Significance CRC patients with KRAS mutations are confronted with limited targeted therapeutic options. In this study, we have shown that the median survival time for KRAS -mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. Metformin is preferentially accumulated in KRAS -mutation CRC cells in both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Colorectal Cancer Treatments and Studies
Share to Metabolism, Diabetes, and Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32444490
DOI: 10.1073/pnas.1918845117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1PMID 32444490Read ↗

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancerSemantic proximity Read ↗

Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.Semantic proximity Read ↗

Anti-tumor activity of metformin: from metabolic and epigenetic perspectivesSemantic proximity Read ↗

Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR Signaling PathwaysSemantic proximity Read ↗

K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.Semantic proximity Read ↗

Metformin: an old drug with potential therapeutic function in antitumorSemantic proximity Read ↗

Metformin antiproliferative activity is exclusively mediated by the membrane functional expression of the Chloride Intracellular Channel 1 in glioblastoma stem cellsSemantic proximity Read ↗

Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.Semantic proximity Read ↗

A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivoSemantic proximity Read ↗

Metformin decreases <i>Cyp26a1</i> to prevent hepatocarcinogenesis through down- regulating CD8 <sup>+</sup> T cellsSemantic proximity Read ↗

Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effectSemantic proximity Read ↗

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.